Drugs / Ribavirin (RBV)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02332720 | Jan 2015 → Sep 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01846832 Background | Sep 2013 → Aug 2015 | chronic hepatitis C virus infection | Janssen-Cilag International NV | Completed | Missed primary |
| Phase 3 | NCT01288209 Background | Feb 2011 → Sep 2012 | chronic hepatitis C virus infection | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ribavirin (RBV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01288209 ↗ |
| Known as | RBV | “Drug: Ribavirin (RBV)” NCT01846832 ↗ |
| Route | Oral | “taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper” NCT01288209 ↗ |